Abstract
Klebsiella pneumoniae is associated with high resistance to antimicrobials and is common in isolates from colonization and nosocomial infections. This study aims to develop assays to detect resistance genes belonging to the bla family and investigate metabolic pathways in resistant isolates of K. pneumoniae. The genes of the subfamilies included were: blaSHV, bla TEM, bla NDM, bla KPC, bla GES, bla CTX-M and relevant variants of the blaOXA subfamily. Mass spectrometry data were acquired on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Isolates from 122 K. pneumoniae samples were collected from 04/23/2019 to 05/29/2021. A high prevalence of resistance to penicillins, cephalosporins and carbapenems was found among the isolates. The identified genotypic profile showed a high prevalence of genes belonging to Ambler’s classes of beta-lactamases A, B and D. In the metabolomic study, the N-fructosyl isoleucine metabolite was identified increased in multidrug-resistant (MDR) strains of K. pneumoniae compared to strains susceptible to antimicrobials. In conclusion, the assays developed were efficient in detecting the main genes of the bla family of resistance in K. pneumoniae. The use of the pentose phosphate metabolic pathway suggests a benfical regulation of bacterial growt, and colonization in MDR K. pneumoniae strains, with may indicate the use of this pathway as a virulence mechanism in resistant strains.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by by CNPq (http://www.cnpq.br), grant numbers 402607/2018-0 and 408549/2022-0. And FUNCAP (https://www.funcap.ce.gov.br/), grant number: OFíCIO no. 102/2021 - DINOV.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Brazilian National Research Ethics Commission gave ethical approval for this work. Approval number (no. 03300218.2.0000.5054).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
-The blaCTX-M nomenclature used was changed to fit into the international standardization for this gene. -A mistake about the number of variants identifiable by the KPC primer developed was corrected, all the sequences available at NCBI database (N = 208) was tested in silico, and the primer was able to identify all of them. The access number of all the sequences identifiable is available at the supplementary material. -Figure 4 was modified for better undestanding of the captions. -A more detailed introduction and discussion has been added for better undestanding of the metabolomic section. -An acknowledgement to the Biomolecular Analysis Core Facility which is supported by the University of Virginia School of Medicine has been added.
Data Availability Statement
The data and reports relating to this study will be available via direct request via email to the corresponding author.
